ES2042828T3 - Procedimiento de preparacion de vacunas contra tumores modificadas por virus para la inmunoterapia de metastasis de tumores. - Google Patents

Procedimiento de preparacion de vacunas contra tumores modificadas por virus para la inmunoterapia de metastasis de tumores.

Info

Publication number
ES2042828T3
ES2042828T3 ES89103480T ES89103480T ES2042828T3 ES 2042828 T3 ES2042828 T3 ES 2042828T3 ES 89103480 T ES89103480 T ES 89103480T ES 89103480 T ES89103480 T ES 89103480T ES 2042828 T3 ES2042828 T3 ES 2042828T3
Authority
ES
Spain
Prior art keywords
immunotherapy
tumor
preparation procedure
vaccine preparation
virus modified
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES89103480T
Other languages
English (en)
Spanish (es)
Inventor
Volker Prof Dr Schirrmacher
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6348527&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2042828(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Application granted granted Critical
Publication of ES2042828T3 publication Critical patent/ES2042828T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18133—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
ES89103480T 1988-03-01 1989-02-27 Procedimiento de preparacion de vacunas contra tumores modificadas por virus para la inmunoterapia de metastasis de tumores. Expired - Lifetime ES2042828T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE3806565A DE3806565A1 (de) 1988-03-01 1988-03-01 Virusmodifizierte tumorvakzinen fuer die immuntherapie von tumormetastasen

Publications (1)

Publication Number Publication Date
ES2042828T3 true ES2042828T3 (es) 1993-12-16

Family

ID=6348527

Family Applications (1)

Application Number Title Priority Date Filing Date
ES89103480T Expired - Lifetime ES2042828T3 (es) 1988-03-01 1989-02-27 Procedimiento de preparacion de vacunas contra tumores modificadas por virus para la inmunoterapia de metastasis de tumores.

Country Status (10)

Country Link
US (1) US5273745A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (1) EP0331102B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JPH02504034A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR900700130A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (1) ATE90877T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU3188989A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (2) DE3806565A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (1) DK541889D0 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES2042828T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO1989007946A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3922444A1 (de) * 1988-03-01 1991-01-10 Deutsches Krebsforsch Virusmodifizierte tumorvakzine fuer die immuntherapie von tumormetastasen
DE4204132C2 (de) * 1991-02-12 1997-12-18 Rudolf Dr Pekar Aufbereitung für die Gewinnung von Vakzinen für eine Immuntherapie
DE69232890T2 (de) * 1991-10-04 2003-10-09 The Johns Hopkins University School Of Medicine, Baltimore Regulierung der systemischen immunantworten mittels zytokinen und antigenen
ATE411809T1 (de) * 1993-04-30 2008-11-15 Wellstat Biologics Corp Zusuammensetzungen zur behandlung von krebs mittels viren
DE19506483A1 (de) * 1995-02-24 1996-08-29 Jens Dr Dr Atzpodien Lyophilisat-Vakzine
US6406689B1 (en) 1995-10-03 2002-06-18 Frank W. Falkenberg Compositions and methods for treatment of tumors and metastatic diseases
EP0805207A1 (en) * 1996-05-02 1997-11-05 Gesellschaft für Biotechnologische Forschung mbH (GBF) Polycistronic expression plasmid for tumor rejection
ATE245163T1 (de) * 1996-05-03 2003-08-15 Univ Jefferson Impfstoff gegen metastasierenden kolorektalkrebs.
CA2242590A1 (en) * 1996-10-04 1998-04-09 Thomas Jefferson University T cells mediating an immune response and methods of use
DE69731950T2 (de) * 1997-08-22 2005-05-19 Science Park Raf S.P.A. Tumorvakzinierung mittels Verwendung autologer oder HLA-verwandter Antigen präsentierender Zellen (APC), die mit einem Tumorantigen sowie einem eine Immunantwort hervorrufenden Fremdantigen transduziert sind
TW575420B (en) * 1997-09-22 2004-02-11 Kirin Brewery Composition for enhancing cellular immunogenicity comprising alpha-glycosylceramides
US20030044384A1 (en) * 1997-10-09 2003-03-06 Pro-Virus, Inc. Treatment of neoplasms with viruses
US7470426B1 (en) 1997-10-09 2008-12-30 Wellstat Biologics Corporation Treatment of neoplasms with viruses
WO2000062735A2 (en) * 1999-04-15 2000-10-26 Pro-Virus, Inc. Treatment of neoplasms with viruses
US7780962B2 (en) * 1997-10-09 2010-08-24 Wellstat Biologics Corporation Treatment of neoplasms with RNA viruses
US8147822B1 (en) 1999-09-17 2012-04-03 Wellstat Biologics Corporation Oncolytic virus
EP1092439A1 (en) * 1999-10-13 2001-04-18 Thorsten Dr. Ahlert Activation of antigen-specific T cells by virus/antigen-treated dendritic cells
RU2172182C1 (ru) * 2000-07-27 2001-08-20 Бритов Василий Александрович Способ профилактики и лечения заболеваний иммунной системы и средство для его осуществления
KR20040094635A (ko) * 2003-05-02 2004-11-10 주식회사 엠디바이오알파 항종양 활성의 유도를 위한 종양 백신의 제조방법 및그것을 함유하고 있는 약제 조성물
ES2668464T3 (es) 2005-12-02 2018-05-18 Icahn School Of Medicine At Mount Sinai Virus quiméricos de la enfermedad de Newcastle que presentan proteínas de superficie no naturales y sus usos
US9283266B2 (en) * 2008-02-28 2016-03-15 University Of Notre Dame Metastasis inhibition preparations and methods
US8586023B2 (en) 2008-09-12 2013-11-19 Mie University Cell capable of expressing exogenous GITR ligand
US20110206736A1 (en) * 2008-09-23 2011-08-25 Thomas Jefferson University Cancer Vaccines Against Mucosal Antigens and Methods of Making and Using the Same
EP2327764B1 (en) * 2009-11-30 2011-12-28 United Cancer Research Institute New clone of Newcastle disease virus, its manufacture and its application in the medical treatment of cancer
SG10201802982WA (en) 2013-03-14 2018-06-28 Icahn School Med Mount Sinai Newcastle disease viruses and uses thereof
CA2940570A1 (en) 2014-02-27 2015-09-03 Viralytics Limited Combination method for treatment of cancer
JOP20190256A1 (ar) 2017-05-12 2019-10-28 Icahn School Med Mount Sinai فيروسات داء نيوكاسل واستخداماتها
US12391957B2 (en) 2018-08-17 2025-08-19 Icahn School Of Medicine At Mount Sinai Recombinant Newcastle disease viruses and uses thereof for the prevention of RSV disease or human metapneumovirus disease

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2918927A1 (de) * 1979-05-10 1980-11-20 Hans Prof Dr Limburg Arzneipraeparat zur behandlung von carcinomen und verfahren zu dessen herstellung
DE3432714A1 (de) * 1984-09-06 1986-04-24 Behringwerke Ag, 3550 Marburg Tumortherapeutikum und verfahren zu seiner herstellung
HU197517B (en) * 1984-07-30 1989-04-28 Laszlo Csatary Process for production of terapeutical composition applicable against virus infection

Also Published As

Publication number Publication date
DE58904760D1 (de) 1993-07-29
EP0331102A1 (de) 1989-09-06
EP0331102B1 (de) 1993-06-23
KR900700130A (ko) 1990-08-11
AU3188989A (en) 1989-09-22
JPH02504034A (ja) 1990-11-22
DK541889A (da) 1989-10-31
DK541889D0 (da) 1989-10-31
US5273745A (en) 1993-12-28
DE3806565A1 (de) 1989-09-14
ATE90877T1 (de) 1993-07-15
DE3806565C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1991-04-25
WO1989007946A1 (en) 1989-09-08

Similar Documents

Publication Publication Date Title
ES2042828T3 (es) Procedimiento de preparacion de vacunas contra tumores modificadas por virus para la inmunoterapia de metastasis de tumores.
ES2150493T3 (es) Adyuvantes para vacunas contra el virus sincitico respiratorio.
CY1110359T1 (el) Εμβολια με βαση σιρκοϊους χοιρων
CY1106635T1 (el) Ανοσοενισχυτικο που περιεχει ν - φορμυλο μεθειονυλο-πεπτιδια για εμβολια
ES2179105T3 (es) Adyuvantes proteinicos.
DK0538437T3 (da) Immunstimulerende og immunforstærkende, rekonstituerede influenzavirosomer og vacciner indeholdende dem
ES2006925A6 (es) Procedimiento para la preparacion de vectores de expresion.
CO4960659A1 (es) Vacuna que comprende un antigeno de virus de la hepatitis b y un antigeno del virus herpes simplex
DK1216053T3 (da) Influenzavaccine
CY1106848T1 (el) Τροποποιημενος ιος vaccinia ankara για τον εμβολιασμο νεογνων
AR011216A1 (es) Una vacuna a base de antigenos superficiales contra la gripe, un metodo para prepararla y un metodo para la preparacion de proteinas antigenicas superficiales a partir de virus de gripe propagados sobre un cultivo celular animal
FI102382B1 (fi) Ilmentämisjärjestelmä ihmisen respiratory syncytial -viruksen glykoproteiinien immunogeenisia fragmentteja sisältäviä kimeerisiä glykoproteiineja varten
FI905184A0 (fi) Kimeriska glykoproteiner som innehaoller immunogeniska delar av human parainfluensa-virus typ 3.
ES8900007A1 (es) Un metodo para producir normas orales frente a virus de hepatitis-b.
ES2078971T3 (es) Produccion de virus y purificacion de proteinas con envoltura virica para uso en vacunas.
ES553758A0 (es) Un metodo para preparar proteinas que son inmunologicamente reactivas con anticuerpos para virus asociados con linfadenopatia.
ES495939A0 (es) Un procedimiento de preparacion de una vacuna de virus vivosde la peritonitis infecciosa de los felinos
ES2148355T3 (es) Procedimiento para la preparacion de nevirapina.
ES2087111T5 (es) Vacuna sintetica para la induccion especifica de linfocitos t citotoxicos.
ES553425A0 (es) Perfeccionamientos en la fabricacion de conjugados de proteinas portadores de antigenos inmunogenicos para vacunas contra la malaria
Arimilli et al. Engineered expression of the TLR5 ligand flagellin enhances paramyxovirus activation of human dendritic cell function
ZA941853B (en) Stimulation of immune response by viral protein
EP0332241A3 (en) Live combination vaccine
ES550089A0 (es) Procedimiento para producir una vacuna coadyuvada que contiene un antigeno seleccionado de proteinas, bacterias y virus.
SE8700466D0 (sv) Vaccines against melanoma

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 331102

Country of ref document: ES